

Transmitted herewith is a copy of the "Sequence Listing" (sheets 1/14 through 14/14) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicants' Attorney hereby states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicants' Attorney submits the following amendments to comply with 37 C.F.R. §1.825:

In the Specification

Please insert the attached "Sequence Listing" (sheets 1/14 through 14/14), and comprising SEQ ID NOS: 1-8, into the above-referenced application.

On page 6, line 6, delete "572" and insert --567--.

On page 12, line 31, delete "572" and insert --567--.

On page 13, line 3, delete "572" and insert --567--.

On page 13, after line 15 and prior to the heading Uses of the Cloned TGF- β Receptors and Related Products, insert the following new paragraph:

Plasmid 3FF was deposited in accordance with the provisions of the Budapest Treaty at the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, VA, 20110-2209, U.S.A. on November 12, 1997, and assigned Accession Number ATCC 209455.--

REMARKS

Sequence Listing

In comparing the nucleotide and amino acid sequences of the TGF- β type II receptor as originally filed, with the corresponding sequences published in the Lin, H., *et al.*, *Cell*, 68:775-785 (1992) paper (the Lin *et al.* paper), Applicants' Attorney discovered discrepancies between